Shots:

• The two companies collaborated to develop and distribute innovative digital therapeutics supporting people with diabetes on biologics therapy. The collaboration allows Biocon to offer Insulia to T2D patients across several markets globally
• Biocon aspires to reimagine the patient ecosystem by developing a technology-dependent operating model enabling personalization of care- thus going beyond the product to reduce both the cost of the drug as well as the cost of administering the drug
• Insulia is the US FDA cleared and CE-marked digital therapeutic with regulatory clearance to provide automated titration recommendations for all types of basal insulins. Biocon is extending the Insulia platform to its complete range of insulin products- including Recombinant Human Insulin- Insulin Glargine and Insulin Aspart- creating a digital therapeutics portfolio for patients

  Ref: Biocon | Image: Medical Dialogues